主页 > 生命科学 >
【medical-news】血管紧张素II抑制剂可以降低皮肤癌
http://www.medscape.com/viewarticle/579786
NEW YORK (Reuters Health) Aug 28 - Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) appears to lower the incidence of basal cell and squamous cell carcinoma among people at high risk, according to a study among US veterans.
Evidence from in vivo and in vitro studies suggests that angiotensin II is a potent angiogenic and growth factor, Dr. Jennifer B. Christian and co-investigators note in the September 3 Journal of the National Cancer Institute, issued online on August 26. There are also indications from epidemiological research that ACE inhibitors and ARBs may protect against cancer.
To examine the effect of these drugs on the risk of keratinocyte skin cancers, the research team analyzed data from a Department of Veterans Affairs trial of topical tretinoin involving 1051 patients deemed to be at high risk of basal cell or squamous cell carcinoma, based on the occurrence of two tumors in the 5 years preceding enrollment between 1998 and 2003.
All subjects were free of cancer at baseline. Approximately half (532) had been prescribed an ACE inhibitor or ARB during the trial or the 3 months prior to enrollment.
A total of 472 basal cell carcinomas and 309 squamous cell carcinomas were diagnosed during a median follow-up of 3.4 years. The combined absolute incidence rates per 1000 person-years were 237 among users of ACE inhibitors/ARBs and 374 among nonusers.
"We were surprised to find such a pronounced reduction in BCC and SCC incidence in users of ACE inhibitor or ARBs in such a high-risk group over a short amount of time," Dr. Christian at Brown University in Providence, Rhode Island, and her associates write.
Compared with nonusers, users of ACE inhibitors or ARBs were at significantly reduced risk of basal cell carcinoma (incidence rate ratio 0.61) and of squamous cell carcinoma (IRR 0.67). The greatest reductions were observed when ACE inhibitors or ARBs were initiated during the study period (IRRs 0.45 and 0.48, respectively), implying "a more immediate effect rather than a delayed effect."
"If these novel findings are confirmed in a randomized controlled trial, they may lead to prevention of these very common cancers, at least among individuals at very high risk."
J Natl Cancer Inst 2008;100:1223-1232. 本人已认领本文翻译48小时若未提交请其他战友继续认领 Angiotensin II Blockade May Reduce Risk of Skin Carcinoma
http://www.medscape.com/viewarticle/579786
NEW YORK (Reuters Health) Aug 28 - Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) appears to lower the incidence of basal cell and squamous cell carcinoma among people at high risk, according to a study among US veterans.
纽约（路透社 健康）8月28日。根据一项在美国老兵中进行的试验，使用血管紧张素转化酶(ACE)抑制剂或血管紧张素受体阻滞剂（ARBs）能降低高风险人群的基底细胞癌和鳞状细胞癌的发生率。
Evidence from in vivo and in vitro studies suggests that angiotensin II is a potent angiogenic and growth factor, Dr. Jennifer B. Christian and co-investigators note in the September 3 Journal of the National Cancer Institute, issued online on August 26. There are also indications from epidemiological research that ACE inhibitors and ARBs may protect against cancer.
Jennifer教授和他的合作研究者在８月２６日发表于互联网上的9月3日版《国立癌症研究所杂志》上写到，体内和体外的研究证据表明血管紧张素II是一种有效的生血管并促进血管生长的因子。
To examine the effect of these drugs on the risk of keratinocyte skin cancers, the research team analyzed data from a Department of Veterans Affairs trial of topical tretinoin involving 1051 patients deemed to be at high risk of basal cell or squamous cell carcinoma, based on the occurrence of two tumors in the 5 years preceding enrollment between 1998 and 2003.
为了检测这些药物对角质化细胞皮肤癌发生率的影响，这个研究小组分析了老兵事务部一项针对维甲酸的试验的数据。试验纳入了１０５１名被认为是有患基底细胞或是鳞状细胞癌高风险的病人，纳入的依据是病人在登记之前的１９９８年到２００３年５年间曾经出现过两个肿瘤。
All subjects were free of cancer at baseline. Approximately half (532) had been prescribed an ACE inhibitor or ARB during the trial or the 3 months prior to enrollment.
所有的受试者都没患癌症。 纽约（路透社 健康）8月28日。根据一项在美国老兵中进行的试验，使用血管紧张素转化酶(ACE)抑制剂或血管紧张素受体阻滞剂（ARBs）能降低高风险人群的基底细胞癌和鳞状细胞癌的发生率。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-12-10 17:11
医学,生命科学网